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Abstract
Background: Prenatal diagnosis of chromosomal abnormalities by cytogenetic analysis is time-
consuming, expensive, and requires highly qualified technicians. Rapid diagnosis of aneuploidies
followed by reassurance of women with normal results can be performed by molecular analysis of
uncultured foetal cells. In the present study, we developed a proteomic fingerprinting approach
coupled with a statistical classification method to improve diagnosis of aneuploidies, including
trisomies 13, 18, and 21, in amniotic fluid samples.
Results: The proteomic spectra obtained from 52 pregnant women were compiled, normalized,
and mass peaks with mass-to-charge ratios between 2.5 and 50 kDa identified. Peak information
was combined together and analysed using univariate statistics. Among the 208 expressed protein
peaks, 40 differed significantly between aneuploid and non aneuploid samples, with AUC diagnostic
values ranging from 0.71 to 0.91. Hierarchical clustering, principal component analysis and support
vector machine (SVM) analysis were performed. Two class predictor models were defined from
the training set, which resulted in a prediction accuracy of 92.3% and 96.43%, respectively. Using
an external and independent validation set, diagnostic accuracies were maintained at 87.5% and
91.67%, respectively.
Conclusion: This pilot study demonstrates the potential interest of protein expression signature
in the identification of new potential biological markers that might be helpful for the rapid clinical
management of high-risk pregnancies.
Background
Trisomies are the largest group of chromosome abnormal-
ities. In particular, trisomies for chromosome 13 (Patau's
syndrome), 18 (Edward's syndrome), or 21 (Down's syn-
drome) constitute an important indication for prenatal
diagnosis, being the three autosomal trisomies found
with significant frequency among live births.
For more than 25 years, the prenatal diagnosis of chromo-
somal abnormalities, based on full karyotyping of fetal
Published: 11 January 2008
Proteome Science 2008, 6:1 doi:10.1186/1477-5956-6-1
Received: 3 October 2007
Accepted: 11 January 2008
This article is available from: http://www.proteomesci.com/content/6/1/1
© 2008 Mange et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Proteome Science 2008, 6:1 http://www.proteomesci.com/content/6/1/1
Page 2 of 9
(page number not for citation purposes)
cells from amniotic fluid (AF), has been the gold standard.
However,  in vitro culture requires sufficient cells, great
technical expertise and time consuming manual proce-
dures. Its main limit is the significant delay in providing
the diagnosis (about 10–20 days), which leads to an inev-
itable and important anxiety period for the parents [1].
More recently, several methods based on fluorescence in
situ hybridisation (FISH) or semi-quantitative fluorescent
PCR (QF-PCR) of short tandem repeats (STRs) have been
developed for rapid detection of aneuploidies in high-risk
pregnancies, allowing a prenatal diagnosis of chromo-
somal abnormalities within 24–48 h. Introduced in the
late 1980s, FISH analysis of uncultured interphase fetal
cells with commercially available multicolour specific
probes is presently routinely performed [2]. Although fast
and reliable, the prenatal detection of aneuploidies by
FISH remains expensive and its use is mainly restricted to
pregnancies with anomalies detected by ultrasonography.
The use of QF-PCR of STR for fast detection of aneuploi-
dies has been applied to trisomy 21 [3]. Since 1993, this
molecular approach has been extensively used by several
groups on a research basis [4-9] and the diagnosis of ane-
uploidies by QF-PCR of STR has now been validated as a
reliable method applicable in laboratories [10,11]. How-
ever, replacement of full karyotypes with rapid testing for
trisomies 13, 18, and 21 by PCR or FISH should result in
substantial numbers of liveborn children with hitherto
preventable mental or physical handicaps [12].
Amniotic fluid is a significant contributor to fetal health
and constitutes a potential rich source of biomarkers for
diagnosis of fetal disorders [13]. Particularly, genetic
abnormalities such as trisomies may induce alterations of
protein expression and/or content which may be useful
for diagnosis of many pathologies. Proteomic studies of
AF have recently been successfully used to detect prema-
ture rupture of membranes [14,15], to diagnose intra-
amniotic infection [16-20] and Down syndrome [21-23].
To identify useful and relevant biomarkers for fetal aneu-
ploidies in AF, we used a method based on initial protein
fractionation by retenate chromatography on protein chip
arrays followed by SELDI-TOF/MS. We examined aneu-
ploidy-specific protein signatures in amniotic fluid of
pregnancies at the 17th week of gestation with trisomies
21, 18 and 13 foetuses, compared to chromosomally nor-
mal ones using 3 chromatographic conditions.
Results
Reproducibility
In order to evaluate the variability of SELDI, we first tested
the experimental reproducibility using a pool of normal
AF, spotted randomly onto each array together with the
tested AF samples. The peaks generated for reproducibility
purposes were obtained using the CM10, Q10, H50 and
IMAC30-Cu chips. The coefficients of variation of 15 reli-
able peaks were calculated by average peak intensity val-
ues derived from 20 different runs. Acceptable average
CVs of 10 and 17% were obtained for intra and inter-assay
variability, respectively, which is consistent with previ-
ously reported studies of SELDI [24,25].
Representative biomarkers: Univariate analysis
Twenty-eight AF samples corresponding to the training set
(15 aneuploidie and 13 normal samples) were analysed
using four different array surfaces. Trisomy 21 was diag-
nosed by standard cytogenetic methods in 9 cases, trisomy
18 in 4 cases, and trisomy 13 in 2 cases. Using the Protein-
Chip and Biomarkers Wizard software, a total of 208 pro-
tein peak clusters in a range of 2.5 to 50 kDa were
obtained from the training set: 52 with the CM10, 79 with
the Q10 and 77 with the IMAC30-Cu arrays. The H50
array was not subjected to analysis due to the weak
number of peaks detected in preliminary experiments.
According to our first statistical criteria, we selected 40
(11, 16 and 13 for CM10, Q10 and IMAC30-Cu, respec-
tively) of 208 protein peaks that were significantly differ-
entially expressed between aneuploidie AF and control
samples (p < 0.05). Among these 40 peaks, 12 of them
were overexpressed and 28 of them underexpressed in
aneuploidie AF as compared to the control samples. Diag-
nostic values of each of these 40 differentially expressed
peaks were high, with an AUC of the receiver operator
characteristic curve (AUC-ROC) ranging from 0.71 to 0.91
according to the different protein peaks. A representative
example of 3 discriminating protein peaks are shown in
Figure 1 and the mean intensity, the p-value and the AUC
value of the 40 peaks were given in Table 1.
Representative Biomarkers: Multivariate Analysis
A heat cluster map, indicating up and down regulation of
possible biomarker candidates, was generated for a multi-
variate analysis of the samples in a training set. The heat
cluster map generated represents all the possible biomar-
ker peaks between 2.5 and 50 kDa, from all three protein
chips, in which differences in expression were observed
between normal and aneuploid amniotic fluids. On the
basis of the colour pattern (red indicating up regulation
and green indicating down regulation) generated, it is
clear that differences exist between normal samples com-
pared to the aneuploid samples (Figure 2A). Upon closer
observation of the heat cluster map, it is apparent that 3
aneuploid samples (2 trisomies for chromosome 18 and
one for chromosome 21) were misclustered and have
more possible biomarkers in common with the normal
samples as compared to the aneuploid samples. In addi-
tion to the heat cluster map, a second multivariate analy-
sis was generated using a PCA diagram. The PCA allowed
us to visualize the relationship between the normal andProteome Science 2008, 6:1 http://www.proteomesci.com/content/6/1/1
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aneuploid samples in a three-dimensional view based on
all the potential biomarkers identified. Blue circles repre-
sent normal samples in contrast to the red circles, which
represent aneuploid samples. Based on the PCA diagram,
we could conclude that the same 3 amniotic and 3 normal
samples are still misclassified (Figure 2B). Markers chosen
as representatives had a p < 0.05 indicating their signifi-
cance.
To construct a multivariate classifier for aneuploidies, we
used the 208 protein peaks obtained by SELDI analysis to
train a SVM classification algorithm taking into account
biomarker inter-correlations. SVM is a supervised learning
technique that constructs an optimal separating hyper-
plane from the training set with an aim of classifying the
test set [26-28]. It achieved an overall classification accu-
racy of 92.86%, sensitivity of 93.33%, and specificity of
92.31% in distinguishing normal samples from aneu-
Table 1: Forty statistically significant protein peaks are differentially expressed in normal and aneuploid AF samples
Peak intensity (d)
m/z (a) Surface array p-value (b) AUC (c) Normal Aneuploidies Fold Change
6080 CM10 0.00001 0.918 1.66 9.50 5.7
2876 CM10 0.0006 0.861 6.37 20.96 3.3
15944 IMAC 0.0013 0.838 4.12 1.99 0.5
3023 CM10 0.0015 0.837 10.06 27.88 2.8
7970 IMAC 0.0016 0.833 4.78 2.67 0.6
6194 CM10 0.003 0.817 1.55 9.75 6.3
3903 IMAC 0.0037 0.810 7.85 2.90 0.4
8455 CM10 0.0065 0.793 38.28 26.92 0.7
22214 CM10 0.0065 0.793 0.30 0.16 0.5
9626 IMAC 0.0068 0.790 5.19 3.01 0.6
24720 Q10 0.0079 0.781 0.58 0.48 0.8
9467 IMAC 0.0105 0.776 6.05 4.02 0.7
3173 Q10 0.0118 0.768 4.64 2.04 0.4
18977 IMAC 0.012 0.771 0.61 0.29 0.5
4323 Q10 0.0134 0.763 5.66 9.47 1.7
5655 Q10 0.0134 0.763 5.47 2.92 0.5
14017 IMAC 0.0137 0.767 4.82 2.65 0.5
3184 CM10 0.0151 0.764 2.93 8.41 2.9
3435 IMAC 0.0157 0.762 2.66 9.04 3.4
8660 CM10 0.0172 0.760 4.95 3.00 0.6
9276 IMAC 0.0178 0.757 1.90 4.11 2.2
12289 IMAC 0.0178 0.757 4.97 3.33 0.7
15056 Q10 0.0194 0.750 0.78 1.31 1.7
3383 CM10 0.0196 0.755 7.24 12.71 1.8
13761 IMAC 0.0202 0.752 6.15 4.10 0.7
7655 Q10 0.0245 0.741 4.52 6.56 1.5
14014 Q10 0.0245 0.741 4.56 2.72 0.6
11670 CM10 0.0251 0.744 3.19 1.92 0.6
4954 IMAC 0.0259 0.743 14.73 10.19 0.7
7007 Q10 0.0275 0.737 3.85 1.98 0.5
6892 Q10 0.0308 0.732 4.34 3.26 0.8
8203 Q10 0.0308 0.732 5.80 3.45 0.6
9159 Q10 0.0308 0.732 9.03 7.82 0.9
11314 Q10 0.0344 0.728 6.90 4.10 0.6
8574 IMAC 0.0367 0.729 12.48 7.55 0.6
4519 Q10 0.0472 0.714 1.44 2.27 1.6
4901 Q10 0.0472 0.714 3.61 2.25 0.6
13809 Q10 0.0472 0.714 4.20 2.73 0.6
49297 Q10 0.0472 0.714 0.21 0.16 0.8
11303 CM10 0.0499 0.716 2.62 1.90 0.7
a) m/z: mass/charge ratio of the protein peak.
b) P-values were calculated using parametric Mann-Whitney test.
c) AUC (area under the ROC curve) were calculated using normal amniotic fluids as reference.
d) Averages of peak intensities.Proteome Science 2008, 6:1 http://www.proteomesci.com/content/6/1/1
Page 4 of 9
(page number not for citation purposes)
ploid samples. To construct a multivariate classifier, we
also performed a preselection step to allow an optimal
identification of differentially expressed peaks. Logistic
regression was used to construct a multiprotein classifier
composed of two protein peaks (CM10, 6194 kDa- and
Q10, 3173 kDa). The composite index yielded higher
AUC value (0.928) than the individual protein peaks
(0.817 and 0.768). Table 2 indicates the mean perform-
ance of both classification methods. In order to validate
our classifiers, we next performed an independent valida-
tion test on 24 AF samples (12 normal and 12 aneuploid
samples). SVM algorithm was used to classify the test set.
Trisomy 21 was diagnosed by standard cytogenetic meth-
ods in 8 cases, trisomy 18 in 3 cases, and trisomy 13 in 1
case. Results indicated that overall classification accura-
cies were maintained in the validation phase with 87.5%
(sensitivity 83.33%, specificity 83.33%) and 91.67%
(sensitivity 83.33%, specificity 100%) for SVM classifica-
tion and logistic regression indexes, respectively. Consid-
ering an estimated prevalence of aneuploidies in the
general population of 1/800 [29], we evaluated the PPV
and the NPV for both classifiers (Table 2).
Discussion
With the development of obstetric ultrasound examina-
tions for prenatal care, fetal anomalies are often found
without the objective of diagnosis [30]. These findings do
not allow identification of a specific chromosome region
as a target for prenatal diagnosis. Although microarray
analyses have been used to identify many molecular
events and to analyse variations in gene expression associ-
ated with aneuploidies [31-33], the level of mRNA expres-
sion does not systematically reflect the proteome in a cell.
Indeed, translation of mRNA into proteins depends on
several post-transcriptional and post-translational events
(glycosylation, phosphorylation, acetylation, etc.).
Hence, direct measurement of protein expression may
determine cell dysfunction more effectively. Proteome
Representative SELDI-TOF spectra (left panel) and gel (right panel) views of selected biomarkers obtained from normal and  aneuploid AF samples Figure 1
Representative SELDI-TOF spectra (left panel) and gel (right panel) views of selected biomarkers obtained from normal and 
aneuploid AF samples. For both protein peaks, the data of three normal karyotypes samples (N, upper panel) and three aneu-
ploidy karyotypes samples (A, lower panel) are shown. Frames indicate the positions of two peaks at 2876 and 3023 Da, 
respectively, both overexpressed in aneuploid samples. Overlay of protein mass spectra is represented in the upper box. Pro-
tein mass spectra obtained from aneuploid (red) and normal (blue) AF are superimposed.Proteome Science 2008, 6:1 http://www.proteomesci.com/content/6/1/1
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analysis is based on the combination of three technolo-
gies: a resolutive method for separating proteins as a func-
tion of different physico-chemical criteria (mass, pI,
hydrophobicity, etc.), mass spectrometry (MS) and bioin-
formatic tools. It is therefore possible to identify proteins
from MS data and quantitatively analyse their expression
simultaneously. Bi-dimensional gel electrophoresis cou-
pled with MALDI-TOF MS (Matrix Assisted Laser Desorp-
tion Ionization – Time of Flight) remains the most
powerful resolutive method to separate complex mixtures
Table 2: Diagnostic performance of classifiers
Tested population General population
Model Accuracy Sensitivity Specificity PPV NPV PPV NPV
SVM multiprotein index
Learning population 92.86 93.33 92.31 93.33 92.31 1.50 99.99
Testing population 87.50 83.33 83.33 83.33 83.33 0.62 99.97
Logistic regression multiprotein index
Learning population 96.43 93.33 100.00 100.00 92.86 100.00 99.99
Testing population 91.67 83.33 100.00 100.00 87.71 100.00 99.98
Positive Predictive Value (PPV) and Negative Predictive Value (NPV) were estimated for the tested population and for the general population (with 
a prevalence of 1/800).
Heat cluster map and principle component analysis (PCA) of aneuploidie amniotic fluid and normal samples Figure 2
Heat cluster map and principle component analysis (PCA) of aneuploidie amniotic fluid and normal samples. All 208 protein 
peaks from 2.5 to 50 kDa mass range and 3 different surface arrays were pooled to generate a heat cluster map (A) and PCA 
diagram (B). The PCA diagram illustrates the segregated samples based on normal (white circles) and aneuploidie (black circles) 
samples.Proteome Science 2008, 6:1 http://www.proteomesci.com/content/6/1/1
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of proteins and to compare variations of protein expres-
sion in a pair of samples, such as normal versus tumour.
The proteins of interest are identified by their peptide
mass fingerprints, obtained after trypsin digestion in gel.
This approach has been used in several studies since 2004
to identify potential biomarkers in amniotic samples for
detection of premature rupture of membranes [14] and
trisomy 21 [22,34]. Although bi-dimensional gel electro-
phoresis has proved effective in many fields, its use in
clinical proteomics is limited. Indeed, it has a labour-
intensive and time-consuming nature rendering analysis
of more than ten samples impossible. Therefore, it is only
of limited value at the condition when tested individuals
may elicit significant biological variations, such as those
in multiple normal tissues from the same organ obtained
from a group of normal individuals or those in different
tumours of the same type of cancer but derived from dif-
ferent patients.
Recently, progresses in nanotechnologies based on liquid
or surface-affinity chromatography have generated new
broadband proteomic analysis techniques for application
to diagnosis of human diseases. SELDI-TOF combines sur-
face-affinity chromatography and mass spectrometry. It
separates and detects peptide and protein peaks from var-
ious biological samples such as amniotic fluid, LCR,
serum or tissue. Using the automated clinical proteomic
method, hundreds of samples can be analysed within a
short period of time allowing statistical analyses to detect
significant differences between two groups of samples
beyond the presence of individuals' biological variations
[35]. SELDI-TOF has been previously used to detect aneu-
ploidies in amniotic fluid [21,23]. Bush et al. described a
clustering algorithm based on protein profiles obtained
from H50 and SAX2 chip surfaces. Wang et al proposed a
two-step proteomic analysis model based on a C18 puri-
fication set followed by a weak cation exchange. Both
studies presented their classification method but did not
clearly indicate discriminatory protein peak molecular
weights, rendering an independent validation study not
realizable. In our study, we have identified, using SELDI-
TOF, the MS-generated proteomics profiles from 52
uncultured amniotic fluids to be able to distinguish nor-
mal foetuses from those with abnormal karyotypes. We
found in an univariate analysis 40 peaks as potential
biomarkers, of which 12 were overexpressed and 28
underexpressed, in aneuploid AF as compared to the con-
trol samples. All were considered statistically significant (p
< 0.05) and AUC values were correct, proving the validity
of their accuracy. The most important steps in proteomic
studies were the differential and statistical analysis of all
data from the spectra. To analyse our data, we searched for
a combination of methods that could reliably detect ane-
uploidies in a high-risk group of women. Since there is no
"gold-standard" method for classification of mass spec-
trometry data, we were interested in testing the validity
and robustness of our methods. Using a SVM classifica-
tion algorithm, we observed a classification accuracy of
92.9% with a sensitivity of 93.3%, and specificity of
92.3%. Since one of the challenges of SELDI data is to
reduce the high-dimension of the spectra, we also
extracted combination of markers from all the 208 pro-
tein peaks by logistic regression. This analysis identified
combination of two protein peaks with an AUC of 0.928,
a classification accuracy of 96.4%, a sensitivity of 93.3%
and a specificity of 100%. Importantly, these values
remained high in an independent validation set proving
the robustness of these methods. Considering the sensitiv-
ity and specificity of our classifiers and the expected prev-
alence of aneuploidies in the general population, one can
expect an extrapolated PPV of 0.4% and a NPV of 99.99%
for the SVM classifier index, and a PPV of 100% and a NPV
of 99.98% for the logistic regression classifier index. Thus,
our proteomic classifiers could be more particularly used
to rapidly screen, within two hours, for aneuploidies in a
high-risk population in whom amniocentesis is indicated
and when the diagnosis is urgently need. Due to the rela-
tively high sensitivity and the perfect NPV of the test, we
minimized the risk of missing an affected pregnancy.
However, clinical trials with more samples are needed to
verify the interest of this rapid detection by proteomic
analysis.
The discriminating proteomic profiling model used in this
study may show some limits. In particular, some aneu-
ploid samples were misclassified (two trisomies 18 and
one trisomy 21). The discrepancy between the cytogenetic
and the molecular results may be explained by the fact
that we analysed AF samples derived from various abnor-
mal karyotypes as a group. In addition, we cannot exclude
some sample contaminations with maternal cells. It
would be interesting to discard all amniotic fluids sus-
pected of blood cell contamination (determined by
microscopic examination for red blood cells). This should
allow the reallocation of some of these individuals into
the correct group. Other limitation is that we analyzed AF
samples from different aneuploidies as a group. Then,
whether we are unable to specify trisomy 21, 18 or 13
markers individually, we can detect rapidly various types
of aneuploidies in one experiment, extending the poten-
tial of clinical application. Increasing number of samples
in further studies should allow to individualise markers
for specific trisomies detection.
We are convinced that, for the moment, none of the dif-
ferent proteomic approaches will replace chromosome
analysis and karyotyping on cultured amniocytes [12].
However, a major drawback of this procedure is the neces-
sity for viable cells to culture for prenatal diagnosis, which
may take up to 2 weeks. Prenatal diagnosis based onProteome Science 2008, 6:1 http://www.proteomesci.com/content/6/1/1
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amplification of STR detection and amplification on
uncultured amniotic cells has proved reliable, avoiding
the need to culture cells and reducing the time required
for a diagnosis. However, this technique is time-consum-
ing and requires intact cells. Our proteomic assay was
designed for a rapid detection of common trisomies of
chromosome 13, 18 and 21, focusing on high-risk preg-
nancies with anomalies detected by ultrasonography, as
an alternative to FISH or PCR quantitation assay. Our
results should be considered as screening or preliminary
tests of aneuploidies in high-risk pregnancies that should
be confirmed by cytogenetic analysis. In addition, this
proteomic method allows further research to be con-
ducted in this area, in particular, in serum samples of
women with normal and aneuploidy fetuses for non-inva-
sive prenatal diagnosis.
Conclusion
In conclusion, this report describes a proteomic approach
combining ProteinChip technology and rule-based analy-
sis that allow a screening for fetal aneuploidies with good
accuracies. The assay could be used as an adjunct for tra-
ditional cytogenetic analysis as proposed by PCR quanti-
tation array or FISH analysis. This preliminary study
supports the view that SELDI-TOF is a valuable tool to
identify biomarkers for aneuploidies diseases in amniotic
fluid but also in serum.
Methods
Supernatant specimens of amniotic fluid
A total of 52 pregnant women underwent amniocentesis
for prenatal chromosome analysis between gestational
weeks 14 and 17. These women were referred to the pre-
natal diagnosis unit of the university hospitals of Cler-
mont-Ferrand and Montpellier. The referral criteria were
maternal age (38 years which is the French cut-off age for
free-of-charge karyotyping), positive biochemical screen-
ing for Down syndrome, abnormal fetal ultrasonic scan,
positive family history of chromosomal rearrangement, or
parental anxiety. Ethical approval for the study was
obtained under the assumption that results were not
reported to the referring clinicians. Through the transab-
dominal approach, about 20 ml of AF was tapped from
each patient. Conventional chromosome analyses were
carried out for each sample. Two ml of AF were used for
the proteomic study. Amniotic cells were collected by cen-
trifugation at 1500 rpm for 5 min. After removing the
supernatant, cells are frozen at -80°C until analysis.
Before proteomic analysis, cells were lysed in 50 mM Tris
pH 7.5, 100 mM NaCl, 5 mM EDTA, 0.5% Triton X100
and 0.5% CHAPS. Protein concentration was measured
using the EZQ Protein quantitation kit (Molecular
Probes) according to the manufacturer's protocol. From
the 52 samples, training and testing populations were ran-
domly done.
Proteomic analysis
Each AF samples were randomly applied on four different
ProteinChip array surfaces (Ciphergen Biosystem, Inc) in
a 96-well format: hydrophobic (H50), cation-exchange
(CM10), anion-exchange (Q10) and metal binding
(IMAC30-Cu). IMAC arrays were pre-treated twice with 50
µL 100 mM CuSO4 on a shaker for 5 min, followed by
two washes with 100 µL water. ProteinChip arrays were
equilibrated twice with 100 µL binding buffer on a shaker
for 5 min and 50 µL binding buffer was added to the sur-
face spots. Five µg of each sample was added to the bind-
ing buffer and the arrays were incubated for 30 min on a
shaker. Arrays were washed three times with 100 µL bind-
ing buffer, followed by a final water wash. For the H50
arrays the final wash was in binding buffer. Arrays were
removed from the bioprocessor, allowed to air dry and 1
µL of 50% SPA was applied twice to the spots. Binding
buffers used for the different arrays were 10% CH3CN,
0.1% TFA for H50; 100 mM NaAC pH 4.0 for CM10; 100
mM Tris-HCl pH 9.0 for Q10; and 100 mM phosphate
buffer pH 7.0, 500 mM NaCl for IMAC30-Cu. Finally,
arrays were analysed on a PBS-IIc ProteinChip Reader.
Data were averaged over 200 transients for each spot and
were performed in the range of 2.5 to 50 kDa. Training
and testing phases were run in independent experiments.
Reproducibility
Mass detection accuracy of PBSIIc was calibrated exter-
nally by using the All-in-1 protein II molecular mass
standards (Ciphergen Biosystems). Reproducibility was
estimated using a control sample which was randomly
spotted on each chip to measure the variability of fraction-
ation, on-chip spotting, and data acquisition. Intensity
values for the selected peaks were used to calculate coeffi-
cients of variation (CV). The reproducibility analysis was
performed for all surface conditions and spectra were col-
lected following the experimental protocols described
above.
Peak detection
Analysis of peaks was performed using the ProteinChip
and Biomarker Wizard software from Ciphergen Biosys-
tem. Spectra were background subtracted and the peak
intensities were normalized to the total ion current of m/
z between 2.5 and 50 kDa. Automatic peak detection was
performed with the following settings: i) signal-to-noise
ratio at 4 for the first pass and 2 for the second pass, ii)
minimal peak threshold at 15% of all spectra, iii) cluster
mass window at 0.5% of mass. The resulting CSV file con-
taining absolute intensity and m/z ratio was exported into
Microsoft Excel (Microsoft, Redmond) for subsequent
analysis.Proteome Science 2008, 6:1 http://www.proteomesci.com/content/6/1/1
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Statistical data analysis
Univariate statistical analysis of SELDI-TOF peak masses
and relative intensity values was conducted with the non-
parametric Mann-Whitney U-test. Differentially expressed
proteins were defined with a p-value < 0.05. Peak intensity
data were then preprocessed before multivariate statistical
analysis using logarithmic transformation. Data were ana-
lysed using various statistical algorithms such as hierarchi-
cal clustering, principal component analysis (PCA) and
support vector machine (SVM) analysis, implemented in
the MultiExperiment Viewer software (Mev, version 4)
[36]. Hierarchical clustering and PCA were not used as
predictive tools, but purely as a mean to understand and
visualize the data structures being analysed. All m/z values
were subject to average-linkage hierarchical clustering,
using Pearson correlation as a distance metric. The peaks
and samples were organized by creating dendrograms. We
also performed dimension reduction using PCA, which
converted higher-dimensional space spanned by differen-
tial peaks into less-redundant and lower-dimensional
space of several principal components. A class prediction
model was defined from the training samples using SVM.
SVM was chosen because this learning scheme was known
to perform well in the challenging situation in which the
number of samples in the data set is not large compared
with the number of attributes. In our case, the attributes
were the peaks. SVM found the maximum margin hyper-
plane, which was the hyperplane separating the two
classes of samples in a n-dimensional space while maxi-
mizing the distance between the hyperplane and the clos-
est training point. On the other hand, logistic regression
was used for peak selection and to construct a multipro-
tein classifier from all the 208 protein peaks. To maximize
the use of our relatively small data set, we have assessed
the performance of our class prediction models with an
external validation scheme. The classifier was thus used to
predict the class validation samples.
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